Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
77643.500.0573%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Phio Pharmaceuticals Corp

PHIONASDAQ
Trade with Public
Trade with Public
$1.13
0.010.89%
At close: Aug 28, 5:00 PM EST
$1.14
0.010.88%
After Hours: Aug 28, 9:28 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Phio Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Phio Pharmaceuticals (PHIO).

Price Target Range — 7 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$11Upside to Avg. PT+836.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 26, 2026HC Wainwright & Co.Matthew KellerMaintainedBuy$14
Feb 10, 2026HC Wainwright & Co.Matthew KellerMaintainedBuy$14
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14

HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Target of $14.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $4 Price Target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $4 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved